SEC Form 4 · accession 0001171843-18-000049
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter A Kiener
Officer — Chief Science Officer
Period of report
Dec 28, 2017
Accepted (ET)
Jan 2, 2018 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class AF1,F2 | Dec 28, 2017 | F | 27,496 | $17.98 | D | 44,527 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported represents the non-discretionary withholding of shares to satisfy the reporting person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.
- F2Common stock originally granted consists of restricted stocked units; this award was originally scheduled to vest on March 2, 2020, but was accelerated to vest on December 28, 2017.